A Novel AICDA Splice-Site Mutation in Two Siblings with HIGM2 Permits Somatic Hypermutation but Abrogates Mutational Targeting
Abstract Hyper-IgM syndrome type 2 (HIGM2) is a B cell intrinsic primary immunodeficiency caused by mutations in AICDA encoding activation-induced cytidine deaminase (AID) which impair immunoglobulin class switch recombination (CSR) and somatic hypermutation (SHM). Whereas autosomal-recessive AID-deficiency (AR-AID) affects both CSR and SHM, the autosomal-dominant form (AD-AID) due to C-terminal heterozygous variants completely abolishes CSR but only partially affects SHM. AR-AID patients display enhanced germinal center (GC) reactions and autoimmune manifestations, which are not present in AD-AID, suggesting that SHM but not CSR regulates GC reactions and peripheral B cell tolerance. Herein, we describe two siblings with HIGM2 due to a novel homozygous AICDA mutation (c.428-1G > T) which disrupts the splice acceptor site of exon 4 and results in the sole expression of a truncated AID variant that lacks 10 highly conserved amino acids encoded by exon 4 (AID-ΔE4a). AID-ΔE4a patients suffered from defective CSR and enhanced GC reactions and were therefore indistinguishable from other AR-AID patients. However, the AID-ΔE4a variant only partially affected SHM as observed in AD-AID patients. In addition, AID-ΔE4a but not AD-AID patients revealed impaired targeting of mutational hotspot motives and distorted mutational patterns. Hence, qualitative defects in AID function and altered SHM rather than global decreased SHM activity may account for the disease phenotype in these patients..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Journal of clinical immunology - 42(2022), 4 vom: 05. März, Seite 771-782 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dirks, Johannes [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
AD-AID |
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1007/s10875-022-01233-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2078833576 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2078833576 | ||
| 003 | DE-627 | ||
| 005 | 20230512164825.0 | ||
| 007 | tu | ||
| 008 | 221220s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10875-022-01233-5 |2 doi | |
| 035 | |a (DE-627)OLC2078833576 | ||
| 035 | |a (DE-He213)s10875-022-01233-5-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Dirks, Johannes |e verfasserin |0 (orcid)0000-0002-1244-6670 |4 aut | |
| 245 | 1 | 0 | |a A Novel AICDA Splice-Site Mutation in Two Siblings with HIGM2 Permits Somatic Hypermutation but Abrogates Mutational Targeting |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Abstract Hyper-IgM syndrome type 2 (HIGM2) is a B cell intrinsic primary immunodeficiency caused by mutations in AICDA encoding activation-induced cytidine deaminase (AID) which impair immunoglobulin class switch recombination (CSR) and somatic hypermutation (SHM). Whereas autosomal-recessive AID-deficiency (AR-AID) affects both CSR and SHM, the autosomal-dominant form (AD-AID) due to C-terminal heterozygous variants completely abolishes CSR but only partially affects SHM. AR-AID patients display enhanced germinal center (GC) reactions and autoimmune manifestations, which are not present in AD-AID, suggesting that SHM but not CSR regulates GC reactions and peripheral B cell tolerance. Herein, we describe two siblings with HIGM2 due to a novel homozygous AICDA mutation (c.428-1G > T) which disrupts the splice acceptor site of exon 4 and results in the sole expression of a truncated AID variant that lacks 10 highly conserved amino acids encoded by exon 4 (AID-ΔE4a). AID-ΔE4a patients suffered from defective CSR and enhanced GC reactions and were therefore indistinguishable from other AR-AID patients. However, the AID-ΔE4a variant only partially affected SHM as observed in AD-AID patients. In addition, AID-ΔE4a but not AD-AID patients revealed impaired targeting of mutational hotspot motives and distorted mutational patterns. Hence, qualitative defects in AID function and altered SHM rather than global decreased SHM activity may account for the disease phenotype in these patients. | ||
| 650 | 4 | |a Hyper-IgM syndrome type 2 | |
| 650 | 4 | |a AID-ΔE4a | |
| 650 | 4 | |a AD-AID | |
| 650 | 4 | |a Mutational targeting | |
| 650 | 4 | |a Somatic hypermutation | |
| 700 | 1 | |a Haase, Gabriele |0 (orcid)0000-0002-6033-7284 |4 aut | |
| 700 | 1 | |a Cantaert, Tineke |0 (orcid)0000-0002-8911-1502 |4 aut | |
| 700 | 1 | |a Frey, Lea |0 (orcid)0000-0003-4696-4326 |4 aut | |
| 700 | 1 | |a Klaas, Moritz |0 (orcid)0000-0003-2528-3716 |4 aut | |
| 700 | 1 | |a Rickert, Christian H. |0 (orcid)0000-0001-7396-4335 |4 aut | |
| 700 | 1 | |a Girschick, Hermann |0 (orcid)0000-0002-2755-3129 |4 aut | |
| 700 | 1 | |a Meffre, Eric |0 (orcid)0000-0003-4326-0171 |4 aut | |
| 700 | 1 | |a Morbach, Henner |0 (orcid)0000-0002-5819-726X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical immunology |d Springer US, 1981 |g 42(2022), 4 vom: 05. März, Seite 771-782 |w (DE-627)168589001 |w (DE-600)779361-3 |w (DE-576)016104072 |x 0271-9142 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2022 |g number:4 |g day:05 |g month:03 |g pages:771-782 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10875-022-01233-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 936 | b | k | |a 44.00 |q VZ |
| 951 | |a AR | ||
| 952 | |d 42 |j 2022 |e 4 |b 05 |c 03 |h 771-782 | ||